Groupe la Francaise Decreases Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Groupe la Francaise has reduced its holdings in Regeneron Pharmaceuticals by 50%, now owning 8,027 shares valued at approximately $4.92 million.
• Regeneron's latest earnings report showed an earnings per share of $12.89, exceeding expectations and demonstrating a 3.6% revenue increase year-over-year.
• The company recently announced a quarterly $0.88 dividend with a payout ratio of 8.87%, reflecting its commitment to returning value to shareholders.

Groupe la Francaise lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 50.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,027 shares of the biopharmaceutical company's stock after selling 8,034 shares during the quarter. Groupe la Francaise's holdings in Regeneron Pharmaceuticals were worth $4,921,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Adirondack Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC increased its position in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after acquiring an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV increased its position in Regeneron Pharmaceuticals by 9.5% during the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after acquiring an additional 19 shares during the last quarter. Private Trust Co. NA increased its position in Regeneron Pharmaceuticals by 13.1% during the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after acquiring an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its position in Regeneron Pharmaceuticals by 6.2% during the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $7.04 during mid-day trading on Thursday, reaching $579.93. The company's stock had a trading volume of 465,836 shares, compared to its average volume of 1,105,802. The firm has a market capitalization of $61.47 billion, a PE ratio of 14.62, a P/E/G ratio of 1.96 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a fifty day moving average of $554.52 and a two-hundred day moving average of $589.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,210.97.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $11.56 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Ratings Changes

A number of analysts recently commented on the company. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Finally, Morgan Stanley reissued an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.